ALYMSYS vs XALKORI

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated October 9, 2026·How we rate

Possible drug interaction. ALYMSYS and XALKORI are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	ALYMSYS	XALKORI
Rating	72/100	New
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	BEVACIZUMAB-MALY	CRIZOTINIB
Manufacturer	Amneal	Pf Prism Cv
Dosage forms	Injectable	Capsule, Oral pellets
Drug class	—	—
Boxed warning	None	None
Treats	Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms	Non-Small-Cell Lung Carcinoma

alymsys xalkori

Rating

72/100

New

Pharmacy pays

—

Type

Active ingredient

BEVACIZUMAB-MALY

CRIZOTINIB

Manufacturer

Amneal

Pf Prism Cv

Dosage forms

Injectable

Capsule, Oral pellets

Drug class

—

Boxed warning

None

Treats

Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms

Non-Small-Cell Lung Carcinoma

Frequently asked questions

What is the difference between Alymsys and Xalkori?

Alymsys contains Bevacizumab-Maly, while Xalkori contains Crizotinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.